The OBN are holding their two day conference for the life sciences industry on the 1 and 2 April 2025 in London.
The conference will feature a dual track of showcase presentations from R&D companies at the Series A stages, across 14 different therapy areas, sponsors exhibition, networking events and an academic poster presentation.
BioTrinity, now in its 19th year, is OBN's flagship two-day conference for the life sciences industry, designed to catalyse growth for all who attend. The two-day conference programme for 2025 features a dual track of showcase presentations from R&D companies at around the Series A stage, across 14 different therapy areas, a packed business & investment track, sponsors exhibition, networking events, private partnering meetings and an academic poster presentation.
After another sell-out year in 2024, we expect an expanded and refreshed audience of c900 delegates to attend BioTrinity 2025, comprising a mix of early stage and emerging life sciences R&D companies, investors, big pharma, academics, charities, government, and a broad range of valued service providers. Delegates attend from the UK, Europe the U.S, Japan, China, Australia and beyond, and the team welcome discussion with clusters to discuss their delegation requirements.